Navigation Links
Exelixis Receives $150 Million Funding Commitment From Deerfield Management
Date:6/5/2008

SOUTH SAN FRANCISCO, Calif., June 5 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) announced today that the company has entered into an agreement with Deerfield Management, a leading healthcare investment organization and significant Exelixis stockholder, to provide Exelixis with up to $150.0 million in financing through a flexible credit facility. The funds can be drawn at any time over the next 18 months at Exelixis' discretion. Exelixis is under no obligation to draw on the facility and can terminate the facility agreement without penalty at any time. Funds drawn will be repayable five years after signing of the facility agreement and can be repaid in shares of Exelixis common stock, subject to certain restrictions, or cash at any time during the term of the agreement.

"This transaction significantly increases our financial strength and flexibility over the next 18 months, even if we don't draw on the facility," said George A. Scangos, PhD, president and chief executive officer of Exelixis. "We expect that the next few months will provide key insights into our pipeline, the future of our existing collaborations, and potential new collaborations. The Deerfield facility gives us the time to see our way through this period of major pipeline and business milestones and puts us in a position of strength as we advance our various partnering discussions. We are in discussions for a number of transactions, and we want to make sure that we have the ability to work through our options, taking into account the outcome of some of the important milestones that we expect to reach later this year. Our objective is to maximize the long-term value from the development of our pipeline and by having the Deerfield facility in place, we hav
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
2. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
3. Exelixis Announces Closing of Public Offering of Common Stock
4. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
5. Exelixis Announces November 5 Webcast of its 2007 Third Quarter Financial Results Conference Call
6. Exelixis Announces Third Quarter 2007 Financial Results and Business Update
7. Exelixis Sells 80% Stake in Artemis to Taconic
8. Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
9. Exelixis Announces November 27 Webcast of Presentation at the 19th Annual Piper Jaffray Health Care Conference
10. Exelixis Announces November 28 Webcast of Presentation at the Lazard Capital Markets Fourth Annual Healthcare Conference
11. Reminder: Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Shimadzu Scientific Instruments today announces ... spectrophotometer. Offering wavelength scanning from 190 to 1,100 ... applications in a variety of industries, including environmental, ... UV-1280 enables intuitive operation, while the enhanced validation, ...
(Date:1/22/2015)... January 22, 2015 The laboratory information ... has witnessed a number of technological advancements due to ... requirements, growing need to integrate healthcare systems, and increasing ... challenges in system integration. Key players in the market ...
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently was invited to ... on probiotics in San Diego, CA. , The Scripps ... health care professionals. This year’s pre-conference seminar was held on ... Dr. Leyer spoke about the emerging topics and science in ...
(Date:1/22/2015)... SAN DIEGO , Jan. 22, 2015   ... company, and Sequenom, Inc. (NASDAQ: SQNM ... a development agreement for next generation noninvasive prenatal ... Cypher,s genome interpretation technology, called Mantis™, to advance ...
Breaking Biology Technology:Shimadzu’s New Monitored Single-Beam UV-Vis Spectrophotometer Offers Comprehensive Measurement Options in a Compact Body 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 4Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4
... Pipeline Efforts at 27th Annual J.P. Morgan Healthcare Conference ... (Nasdaq: GHDX ) announced today that it ... 18-gene Oncotype DX(R) colon cancer assay. Utilizing more ... the validation study will use prospectively defined endpoints to ...
... Jan. 12 WaferGen Biosystems,Inc. (OTC Bulletin ... gene,expression, genotyping, cell biology and stem cell ... successfully demonstrated the,performance of the company,s SmartChip(TM) ... the platform,s ongoing alpha testing program. ...
... - Trial conducted by Novartis to evaluate safety and ... with ribavirin in patients with genotypes 2 and 3 ... Sciences, Inc. (Nasdaq: HGSI ) today announced ... trial that will evaluate the safety and efficacy of ...
Cached Biology Technology:Genomic Health Announces Commencement of QUASAR Clinical Validation Study for Oncotype DX(R) Colon Cancer Assay 2Genomic Health Announces Commencement of QUASAR Clinical Validation Study for Oncotype DX(R) Colon Cancer Assay 3Genomic Health Announces Commencement of QUASAR Clinical Validation Study for Oncotype DX(R) Colon Cancer Assay 4Genomic Health Announces Commencement of QUASAR Clinical Validation Study for Oncotype DX(R) Colon Cancer Assay 5WaferGen's SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program 2WaferGen's SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program 3WaferGen's SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program 4WaferGen's SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program 5Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C 2Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C 3Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C 4Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C 5
(Date:12/19/2014)... Dec. 18, 2014   LaunchKey , the first decentralized ... and Internet of Things era, today announced the close ... round was led by Metamorphic Ventures with participation from ... VegasTechFund, and others.  LaunchKey has raised $4 million to ...
(Date:12/17/2014)...  HITLAB SM announced today its completion of a ... to current U.S. Food and Drug Administration (FDA) regulations. ... and smart phone application trials utilizing the highest principles ... is determined to improve global healthcare access, quality, and ...
(Date:12/17/2014)... Dec. 16, 2014  Automation is fundamentally transforming the travel ... international borders. Over the past decade, ePassports, biometric readers, ... self process through border control via eGates and Automated ... airports, seaports, and land borders across the globe. ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2
... received $50,000 each to put towards developing technologies such ... to impact genomics research. "We received ... creative and imaginative research ideas," commented Dr. Mark Poznansky, ... to support Ontario,s researchers and their work that might ...
... PITTSBURGH -- From a bike path in Montana ... citizen scientists fanned out last June to capture high-resolution ... hoping for even broader participation in their efforts to ... GigaBlitz, scheduled for the solstice week of Dec. 19-26., ...
... will be diagnosed with a common disorder of the jaw ... TMJ). Because of the inherent biological complexity of TMJD, ... their patients will get better in time or battle chronic ... Scientists affiliated with a large, seven-year study supported by ...
Cached Biology News:200 thousand dollars awarded to genomics researchers to spark new research technology development 2200 thousand dollars awarded to genomics researchers to spark new research technology development 3GigaBlitz event seeks citizen scientists to capture images of nearby biodiversity 2GigaBlitz event seeks citizen scientists to capture images of nearby biodiversity 3Study evaluates risk factors for chronic TMJD 2Study evaluates risk factors for chronic TMJD 3Study evaluates risk factors for chronic TMJD 4Study evaluates risk factors for chronic TMJD 5
{3,8-diamino-5-[3-(diethylmethylammonio)propyl]-6-phenylphenanthridinium diiodide}. ,250 ug/ml Propidium Iodide (PI) in PBS....
... reagents for the isolation of genomic DNA. ... the isolation of genomic DNA from blood. ... the isolation of genomic DNA from plants. ... be used for restriction endonuclease digestion Southern ...
Concentration: 1mg/ml. Antigen: Propidium Iodide ...
Apoptosis Detection Systems and Reagents...
Biology Products: